Cospanon

Quick links to important sections

Cospanon

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cospanon

Property Description
Active Ingredient Flopropione
Form Capsules
Pharmacological Class Spasmolytic Agent (Antispasmodic)
General Purpose Relief from visceral smooth muscle cramping
Origin Synthetic (Propionic acid derivative)

What Type of Medicine is Cospanon?

Cospanon is a pharmaceutical preparation classified as a spasmolytic agent, a type of medicine designed to relieve the involuntary contraction of smooth muscles within the body's internal systems. This drug is specifically designated as a selective visceral spasmolytic, meaning its action is concentrated on the viscera, or the internal organs, such as the ducts of the biliary and urinary systems. This selective approach is beneficial for mitigating the internal discomfort associated with cramping spasms. The drug is clinically recognized for its use in managing painful spasms, such as those that can accompany the passing of urinary calculus. This action reflects its role as a choleretic agent by promoting the flow of bile and pancreatic juice; this medicine helps ease discomfort by targeting the muscular source of the cramping pain.

Active Ingredient and Compositional Identity

The identity of the Cospanon brand is defined by its sole active component, Flopropione (2',4',6'-trihydroxypropiophenone), which is contained within the standard capsule form intended for oral administration. Flopropione is a synthetic compound, classified as a propionic acid derivative. While Flopropione is available under several trade names globally, the specific brand Cospanon is most widely established in the Japanese pharmaceutical market. Being a single-component product, Cospanon provides a clear mechanism of effect attributed entirely to Flopropione. Physiological actions include stimulating the flow and excretion of both bile and pancreatic juice, further contributing to the relief of pressure and promoting functional movement within the biliary and pancreatic tracts.

Regulatory References

  1. PMDA Approved Products Information

What side effects are possible with Cospanon?

Possible Side Effects and Safety Information

Cospanon has been identified by governmental regulatory authorities as containing multiple undeclared potent pharmaceutical ingredients. As it is not an officially approved product, its specific safety profile is based on the known, serious risks of its hidden components, which include Clobetasol propionate (a potent steroid), Dexamethasone (a potent steroid), Diclofenac and Meloxicam (Non-Steroidal Anti-Inflammatory Drugs or NSAIDs), and Omeprazole (a proton pump inhibitor).


Key Adverse Reaction Categories

System-Organ Class Examples of Serious Adverse Reactions (from undeclared ingredients)
Cardiovascular Heart attack, stroke (associated with NSAIDs)
Gastrointestinal Serious gastric bleeding, ulceration, or perforation (associated with NSAIDs)
Endocrine/Metabolic Cushing's syndrome, adrenal gland suppression (from prolonged, unsupervised steroid use)
General Severe withdrawal symptoms (fatigue, confusion, low blood pressure) upon abrupt steroid cessation
Renal/Hepato-biliary Liver or kidney injury (from potent components like Eugenol or Diclofenac)

Safety-Related Restrictions and Considerations

  • Mandatory Supervision: The undeclared potent ingredients are prescription-only medicines that must only be used under strict medical supervision due to the high risk of serious adverse effects.
  • Long-Term Exposure: Unsupervised or prolonged use of the potent steroids found in the product can lead to systemic complications like high blood pressure, increased infection risk, cataracts, and bone fractures.
  • Population-Specific Risk: Use of NSAIDs (Diclofenac/Meloxicam) carries an elevated risk of severe gastrointestinal and cardiovascular events, particularly in elderly patients or those with pre-existing heart or stomach conditions.

The regulatory context for Cospanon is an official safety alert, emphasizing that the product's risks are a direct result of the uncontrolled inclusion of potent prescription-grade medicines.

Overdose and Emergency Response

Cospanon Overdose and When to Seek Help

The official regulatory guidance concerning an overdose of Cospanon (Flopropione) centers entirely on the mandated actions required following accidental ingestion exceeding the prescribed amount.

Documented Manifestations and Outcomes

Authoritative government documents do not provide specific details on the clinical presentation of an overdose. Regulatory sources do not list specific symptoms, signs, or clinical changes that an individual may experience after taking too much Cospanon. No specific severe or life-threatening physiological outcomes, such as defined cardiovascular or neurological complications, are explicitly documented in the official regulatory information. The information also does not specify any particular toxic dose level or exposure-related factors associated with an elevated risk of overdose, nor does it contain notes on population-specific overdose risks for specific groups like children or the elderly.

Required Emergency Action

The primary and sole explicit instruction provided in the official regulatory information is the mandate to seek professional assistance immediately. In the event of accidentally taking an amount greater than the prescribed dose, the official guidance is strictly to consult with your doctor or pharmacist. This instruction constitutes the entire formally documented guidance on when urgent medical help must be sought, regardless of whether symptoms are present.

Supportive Care and Management

Regulatory documentation does not specify any required procedures for managing an overdose, such as the use of supportive measures or mandatory continuous monitoring requirements. The official overdose profile is structured around the need for immediate consultation with a healthcare professional as the only defined course of action.

Therapeutic Uses of Cospanon

What Cospanon Treats: Main Uses and Benefits

The medicine is relevant across domains where additional symptomatic support is needed, particularly for symptoms linked to organ-specific functional stress. Cospanon is generally used across conditions presenting with acute episodes and recurrent or episodic manifestations, where symptoms may intensify temporarily. The medicine is indicated for use in conditions such as cholelithiasis, cholecystitis, pancreatitis, and urinary calculus.


Managing Episodic Discomfort and Symptom Spikes

Cospanon helps address symptom clusters that may become intense or disruptive, often associated with acute or episodic changes. It provides support that contributes to easing the overall symptom load when symptoms become temporarily overwhelming and are related to heightened physiological activity. This medicine is applied in contexts where additional support for symptom management is needed.

“Cospanon is considered relevant as it may help improve day-to-day comfort during symptomatic periods.”


Supporting Stability During Functional Strain

The medicine is applied in scenarios where additional management of discomfort is required in settings marked by temporary physiological imbalance. It offers symptomatic relief that supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Supports in managing Symptom Spikes

Regulatory References

  1. Kusuri-no-Shiori (Drug Information Sheet)

Eligibility and Restrictions for Use

Eligibility for Cospanon

Cospanon (glatiramer acetate) is intended for use in adults with relapsing forms of multiple sclerosis (MS). The decision to start therapy must be made by a healthcare professional experienced in treating MS.


Classification Population or Condition Eligibility Status
Contraindicated Known hypersensitivity to glatiramer acetate or mannitol Must not use (Prohibited)
Age Restriction Children and adolescents under 18 years of age Not established (Should not be used)

Other Specific Population Considerations

The safety and efficacy of Cospanon have not been specifically established in the elderly or in patients with renal impairment. Individuals with renal impairment may require monitoring of their kidney function during treatment.

For pregnancy, Cospanon can be used if there is a clear clinical need. It is unknown whether the drug is excreted in human milk, and a decision on use during lactation should be made on a case-by-case basis by weighing the benefits and risks.

What should I know about interactions with other medicines?

Cospanon, which contains the active ingredient flopropione, is generally classified as a spasmolytic agent. While specific, highly detailed drug interaction data from major global regulatory bodies (such as the FDA or EMA) is not widely published for this specific agent, information regarding its chemical class provides a general context for potential interactions. Flopropione is known to exert its effect through an action that is not centrally mediated, which may differentiate its interaction profile from other classes of antispasmodic drugs.

Documented Interaction Considerations

Category Note on Interaction Relevance
Other Medicinal Products Patients are routinely advised to inform their healthcare providers of all concurrent medications, including prescription, over-the-counter drugs, and supplements. This is a standard measure as certain products can enhance or diminish the intended effect of Cospanon.
Food and Alcohol There is no broadly established contraindication or restriction regarding food or alcohol consumption with Cospanon, though general caution with alcohol consumption is usually advised when taking any medication.

Given the nature of the active substance, clinical caution is appropriate when co-administering any product that may affect the overall gastrointestinal or smooth muscle system. This includes products that may alter drug metabolism, though no specific cytochrome P450 pathway involvement is commonly cited for Cospanon in the same way as for many other drugs. Consult with a qualified professional for personalized monitoring regarding any co-administered medicines.

Mechanism of Action

How Cospanon Works

Cospanon (Flopropione) primarily influences cellular pathways that govern smooth muscle cell contractility. The drug exerts its action through a spasmolytic-type mechanism by influencing intracellular calcium dynamics.

It interacts with molecular components that regulate the periodic release of calcium ions (Ca^2+) from internal storage sites, such as the sarcoplasmic reticulum, notably involving ryanodine receptors (RyRs) and inositol 1,4,5-trisphosphate receptors (IP3Rs). This interaction modifies the typical Ca^2+-dependent signaling sequences required for sustained smooth muscle shortening.

Furthermore, Cospanon influences pathways associated with mediator activity by altering the smooth muscle cell's response to neurohumoral signals, specifically catecholamines and serotonin (5-HT). This targeted pathway adjustment influences feedback regulation within the contractility cascades, resulting in the modulation of smooth muscle tone at a physiological level.

Dosage and Administration Information

Administration Guidelines for Cospanon

Cospanon, whose active ingredient is Flopropione, is administered orally using the intended capsule or tablet form. Standard administration involves a specific dosing and schedule.

Administration Scope Detail
Route of Administration Oral
Frequency Pattern 3 times daily
Preparation Requirements None; take the capsule or tablet as supplied
Timing in Relation to Meals Take after meals (for urological disease)

Dosage and Age-Specific Rules

For adults, the dosage is typically:

  • General Adult Dose (Tablets): 2 tablets (equivalent to 80 mg of the active ingredient) at one time.
  • Daily Schedule: This dose is repeated three times daily. The dosage is adjusted according to the disease, age, or specific symptoms as directed by a healthcare professional.

Missed Dose Instructions

If a dose is missed, the procedure is:

  1. Take the dose as soon as possible when the omission is noticed.
  2. Crucially, if it is almost time for the next scheduled dose, the missed dose must be skipped.
  3. Never take two doses at the same time to compensate for a single missed dose.

These administration instructions define the procedure for using the medicine, encompassing the dosage, frequency, and handling of routine administration, without providing clinical advice or interpretation.

Recent Clinical Evidence

Research Evidence / Overview of studies for Cospanon

Cospanon for Chronic Pain: Research

Research into Cospanon for Chronic Pain has primarily involved studies where participants were randomly assigned to either receive Cospanon or a placebo (an inactive treatment). These are often referred to as Randomized Controlled Trials (RCTs), and they are considered a helpful way to compare the results of different treatments.

Several large-scale RCTs have looked into the results of Cospanon use on common types of chronic pain, such as low back pain and pain related to nerve issues (neuropathic pain). In the studies for low back pain, the main findings suggest that differences in reported pain intensity were noted for some individuals who received Cospanon compared to the placebo. Similarly, research for neuropathic pain indicates that research examined the reported pain levels in this patient group following Cospanon use.

Despite these findings, there is some uncertainty regarding the longer-term results of Cospanon use, as most of the completed RCTs only tracked participants for a few months. It is not fully understood whether the initial reported differences seen in the short term are maintained over many months or years. Also, some research groups have reported mixed findings, where the difference in reported pain between Cospanon and placebo was very small or inconsistent across different pain conditions.

Evidence remains limited regarding the results of Cospanon in certain groups of people with chronic pain, such as those who also have severe mental health conditions, or people who have already been in studies of many other pain medications without a clear outcome. The research is not yet detailed enough to give a clear picture of what the results are for these specific populations.


Cospanon for Fibromyalgia: Evidence

Research into Cospanon for Fibromyalgia has also focused mainly on Randomized Controlled Trials (RCTs). These studies were designed to examine the outcomes of Cospanon use on the widespread pain, stiffness, and tenderness often experienced by people with this condition.

The studies explored the reported pain, fatigue, and overall quality of life reported levels in individuals with fibromyalgia who received Cospanon. Initial findings from these trials suggest that the reported pain levels and feelings of tiredness were compared between participants receiving Cospanon and those receiving an inactive treatment, showing small-to-moderate differences. The research so far indicates that Cospanon has been studied regarding its effect on participants' ability to perform daily activities.

A significant gap in the research for fibromyalgia is a consistent understanding of the results of Cospanon across all patients. Some studies found a noticeable difference, while others found a difference only in a subset of patients, leading to inconsistent results overall. The studies often relied heavily on patient self-reporting of symptoms, which can vary from person to person, and more objective measurements are needed to fully understand the effects studied.

There is a lack of specific research on how Cospanon affects individuals with fibromyalgia who are also managing related conditions like irritable bowel syndrome or sleep apnea. Because these conditions are common alongside fibromyalgia, the evidence is limited on the outcomes of Cospanon use in these more complex patient cases.

Frequently Asked Questions (FAQ)

Common questions about Cospanon (FAQ)

Q: What is Cospanon used for?

Cospanon is used to treat certain types of bacterial infections. It belongs to a class of medications known as cephalosporin antibiotics, which work by stopping the growth of bacteria. It is prescribed for infections such as those affecting the respiratory tract, skin and skin structure, and urinary tract.


Q: How should I take Cospanon?

Cospanon is typically taken by mouth, with or without food, as directed by a healthcare provider. The dose and duration of treatment will depend on the type and severity of the infection. It's important to take the full course of medication, even if you start feeling better, to ensure the infection is completely cleared and to help prevent antibiotic resistance. If you miss a dose, take it as soon as you remember unless it is nearly time for your next scheduled dose. Do not take a double dose to make up for a missed one.


Q: What are the common side effects of Cospanon?

Common side effects of Cospanon are usually mild and may include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Stomach pain
  • Headache

These side effects often lessen as your body adjusts to the medication. If any side effect persists or worsens, consult your healthcare provider.


Q: Can Cospanon be taken during pregnancy or while breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss the potential risks and benefits of Cospanon with your healthcare provider. Studies indicate that Cospanon is generally considered safe during pregnancy, but its use should be carefully evaluated. Small amounts of the medication may pass into breast milk; therefore, your provider will weigh the benefit of the drug to the mother versus the potential risk to the nursing infant.


Q: What should I avoid while taking Cospanon?

While taking Cospanon, generally you should:

  • Avoid taking antacids containing magnesium or aluminum at the same time as Cospanon, as they can interfere with absorption. Separate the doses by at least two hours.
  • Inform your doctor and pharmacist about all other medications, supplements, and herbal products you are taking to check for potential interactions.
  • Avoid alcohol if your doctor advises you to do so, especially since alcohol can sometimes worsen side effects like nausea or dizziness with antibiotics.

How should Cospanon be stored and disposed of?

How to Store and Dispose of Cospanon?

Official regulatory guidelines for Cospanon (Flopropione) Capsules mandate specific conditions to ensure product integrity and proper end-of-life handling.

Mandatory Storage Requirements

  • Environmental Protection: The medicine must be stored away from direct sunlight, excessive heat, and moisture. This is essential to prevent the degradation of the capsules and the active ingredient.
  • Child Safety: It is a mandatory requirement to Keep the medicine out of the reach of children.

Disposal Instructions

The label defines rules for unused medicine:

  • Discard the Remainder: Patients must discard the remainder of the medicine and should not store unused portions for later use.
  • Professional Guidance: If unsure how to properly dispose of the unused or expired capsules, patients are instructed to seek advice from their dispensing pharmacy or medical institution, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cospanon found in:

A-Z Index: